Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials

BACKGROUND: Daratumumab as a monoclonal antibody has shown promising results in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the efficacy and safety of daratumumab-based regimens compared to control regimens have not been fully established. METHODS: The search was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zeng-Yi, Jin, Xiao-Qin, Liang, Qi-Lian, Zhang, Ding-Yue, Han, Han, Wang, Zhen-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519573/
https://www.ncbi.nlm.nih.gov/pubmed/37747011
http://dx.doi.org/10.1097/MD.0000000000035319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519573/
https://www.ncbi.nlm.nih.gov/pubmed/37747011
http://dx.doi.org/10.1097/MD.0000000000035319

Ejemplares similares